Myeloid malignancies often arise from an aging hematopoietic system and are currently incurable due to therapy-resistant, disease-reinitiating leukemic stem cells. In this issue of Cell Stem Cell, Crews et al. (2016) report RNA splice isoform signatures unique to patient-derived leukemic stem cells that constitute a therapeutic Achilles' heel of myeloid leukemia.